4.5 Article

Adjuvant antibiotic-loaded bone cement: Concerns with current use and research to make it work

期刊

JOURNAL OF ORTHOPAEDIC RESEARCH
卷 39, 期 2, 页码 227-239

出版社

WILEY
DOI: 10.1002/jor.24616

关键词

antibiotic-loaded bone cement (ALBC); Biofilm Meeting; local antibiotics; musculoskeletal infection (MSKI)

资金

  1. Stavros Niarchos Foundation
  2. Hospital for Special Surgery, New York, NY
  3. National Institutes of Health [R01 AR069119, R01 AR072513, P50 AR072000, R21AR073321, R01GM124436]
  4. BBSRC [BB/R012415/1] Funding Source: UKRI

向作者/读者索取更多资源

The use of antibiotic-loaded bone cement (ALBC) in treating orthopaedic infections raises concerns about lack of clinical evidence for efficacy, subtherapeutic levels following early release, absence of standardized formulation protocols, and the need for a validated assay to determine the minimum biofilm eradication concentration for specific microorganisms.
Antibiotic-loaded bone cement (ALBC) is broadly used to treat orthopaedic infections based on the rationale that high-dose local delivery is essential to eradicate biofilm-associated bacteria. However, ALBC formulations are empirically based on drug susceptibility from routine laboratory testing, which is known to have limited clinical relevance for biofilms. There are also dosing concerns with nonstandardized, surgeon-directed, hand-mixed formulations, which have unknown release kinetics. On the basis of our knowledge of in vivo biofilms, pathogen virulence, safety issues with nonstandardized ALBC formulations, and questions about the cost-effectiveness of ALBC, there is a need to evaluate the evidence for this clinical practice. To this end, thought leaders in the field of musculoskeletal infection (MSKI) met on 1 August 2019 to review and debate published and anecdotal information, which highlighted four major concerns about current ALBC use: (a) substantial lack of level 1 evidence to demonstrate efficacy; (b) ALBC formulations become subtherapeutic following early release, which risks induction of antibiotic resistance, and exacerbated infection from microbial colonization of the carrier; (c) the absence of standardized formulation protocols, and Food and Drug Administration-approved high-dose ALBC products to use following resection in MSKI treatment; and (d) absence of a validated assay to determine the minimum biofilm eradication concentration to predict ALBC efficacy against patient specific micro-organisms. Here, we describe these concerns in detail, and propose areas in need of research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据